LUNG-MAP

Lung-MAP is a cancer clinical trial designed to quickly and efficiently test new treatments for advanced non-small cell lung cancers - which make up about 85 percent of all lung cancer diagnoses in the United States. Lung-MAP is offered at hospitals and clinics all over the country, making it easier for lung cancer patients to participate and get access to investigational treatments to fight their cancer... Lung-MAP is unique. It's the first precision medicine trial in lung cancer supported by the National Cancer Institute (NCI), part of the federal National Institutes of Health, and is the first major NCI trial to test multiple treatments, simultaneously, under one "umbrella" design - which makes Lung-MAP more flexible and more efficient than typical cancer trials, and speeds the development process for new cancer drugs. Lung-MAP is also an unprecedented public-private partnership, one that not only includes the NCI and its National Clinical Trials Network, led by the SWOG Cancer..